<table style="border:1px solid #adadad; background-color: #F3F1EC; color: #666666; padding:8px; -webkit-border-radius:4px; border-radius:4px; -moz-border-radius:4px; line-height:16px; margin-bottom:6px;" width="100%">
<tbody>
<tr>
<td><span style="font-family:Helvetica, sans-serif; font-size:20px;font-weight:bold;">NIH Director's Blog Daily Digest (Unofficial)</span></td>
</tr>
<tr>
<td> </td>
</tr>
</tbody>
</table>
<table style="font:13px Helvetica, sans-serif; border-radius:4px; -moz-border-radius:4px; -webkit-border-radius:4px; background-color:#fff; padding:8px; margin-bottom:6px; border:1px solid #adadad;" width="100%">
<tbody>
<tr>
<td><a href="https://directorsblog.nih.gov/2025/01/10/could-engineered-immune-cells-be-used-to-treat-people-with-autoimmune-diseases-and-organ-transplants-while-reducing-infection-risks/" style="font-family:Helvetica, sans-serif; letter-spacing:-1px;margin:0;padding:0 0 2px;font-weight: bold;font-size: 19px;line-height: 20px;color:#222;">Could Engineered Immune Cells Be Used to Treat People with Autoimmune Diseases and Organ Transplants while Reducing Infection Risks?</a>
<div style="font-family:Helvetica, sans-serif; text-align:left;color:#999;font-size:11px;font-weight:bold;line-height:15px;">Jan 10th 2025, 09:00</div>
<div style="font-family:Helvetica, sans-serif; color:#494949;text-align:justify;font-size:13px;">
<p><figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="576" src="https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-1024x576.jpg" alt="T cells spray an inflammation cell with a fire extinguisher and vacuum up inflammatory granules" class="wp-image-26892" srcset="https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-1024x576.jpg 1024w, https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-300x169.jpg 300w, https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-150x84.jpg 150w, https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-768x432.jpg 768w, https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-1536x864.jpg 1536w, https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells-180x100.jpg?crop=1 180w, https://directorsblog.nih.gov/wp-content/uploads/2025/01/Engineered-Immune-Cells.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>
<p class="has-small-font-size"><em>In a study, researchers engineered human T cells to suppress the immune system’s response in targeted areas of the body, an approach that has potential for treating people with autoimmune diseases and organ transplants.</em> <em>Credit: Donny Bliss/NIH</em></p>
<p>Millions of people in the U.S. have an <a href="https://www.niaid.nih.gov/diseases-conditions/autoimmune-diseases" target="_blank" rel="noreferrer noopener">autoimmune disease</a>, from type 1 diabetes to inflammatory bowel disease, in which the immune system attacks the body’s own organs, tissues, or cells to cause damage. While treatments that tamp down the immune system can help, they can increase risk for infection or cancer due to systemic immune suppression. Similarly, for people who’ve received an organ or tissue transplant, immunosuppressants used to prevent rejection can leave the whole body vulnerable. What if there was a way to suppress the immune system only right where it’s needed, in tissues or organs at risk for immune attack?</p>
<p>An NIH-supported study reported in <a href="https://www.science.org/doi/10.1126/science.adl4793" target="_blank" rel="noreferrer noopener"><em>Science</em></a> describes a way to do just that by using a cell-based therapy approach. The therapeutic approach involves taking a blood sample from a patient, modifying certain immune cells in the laboratory, and then reintroducing the engineered cells back into the body. Such cell-based therapeutics can be designed to recognize specific molecules to target tissues. This approach is already used to treat many cancers, utilizing a patient’s own engineered immune cells, known as <a href="https://www.cancer.gov/about-cancer/treatment/research/car-t-cells" target="_blank" rel="noreferrer noopener">CAR T cells</a>, to attack and kill their cancer. Inspired by the success of the CAR T-cell example, the researchers behind this new work see the technology they’re developing as a potential platform for tackling many types of immune dysfunction.</p>
<p>In the new study, the team, led by <a href="https://limlab.ucsf.edu/people/wendell.html" target="_blank" rel="noreferrer noopener">Wendell Lim</a> and <a href="https://diabetes.ucsf.edu/people/audrey-parent" target="_blank" rel="noreferrer noopener">Audrey Parent</a>, both at the University of California, San Francisco, started by engineering human CD4+ T cells to become “immunosuppressive” by releasing molecules that could act as brakes on the immune system. The researchers also gave these cells a molecular sensor to guide them to the target tissue in the body and to only produce the immunosuppressive molecules when they were in the target tissue.</p>
<p>They found that the engineered immune suppressor cells worked best when they also produced anti-inflammatory signals and receptors to bind and clear away molecules that would otherwise encourage inflammation. Looking at mouse models of type 1 diabetes, the researchers found that the engineered suppressor cells successfully protected transplanted pancreatic islet cells against an immune attack. Pancreatic islets are cells in the pancreas that make hormones, including insulin, to control blood sugar.</p>
<p>That’s important because the loss of pancreatic islet cells in type 1 diabetes leads to insulin deficiency. While transplants of islet cells can restore insulin production to reverse diabetes, recipients must take immunosuppressive medication to prevent a rejection. When the researchers introduced the engineered suppressor cells into mice that had received a transplant of human islet cells, the engineered cells protected the vulnerable islet cells from an attack by the killer T cells. The new findings therefore suggest it could one day be possible to transplant new islet cells into patients without requiring them to take immunosuppressants that affect the whole body.</p>
<p>While much more study is needed, the researchers suggest that such synthetic suppressor T cells could serve as a readily customizable platform to potentially treat many autoimmune conditions. Engineered immune suppressor cells could also be used to fine-tune CAR T-cell therapies for cancer so that they only attack tumors and not normal tissues, making them less toxic. This paves the way for a future in which there may be many more possibilities for precisely tamping down the immune system in ways that could prove life-changing for transplant recipients and those with type 1 diabetes, as well as many other autoimmune conditions.</p>
<p><strong>Reference:</strong></p>
<p>Reddy NR, <em>et al</em>. <a href="https://pubmed.ncbi.nlm.nih.gov/39636990/" target="_blank" rel="noreferrer noopener">Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs</a>. <em>Science</em>. DOI: 10.1126/science.adl4793 (2024).</p>
<p><em>NIH Support: National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute</em></p></p>
</div>
<div style="font-family:Helvetica, sans-serif; font-size:13px; text-align: center; color: #666666; padding:4px; margin-bottom:2px;"></div>
</td>
</tr>
</tbody>
</table>
<p><strong>Forwarded by:<br />
Michael Reeder LCPC<br />
Baltimore, MD</strong></p>
<p><strong>This information is taken from free public RSS feeds published by each organization for the purpose of public distribution. Readers are linked back to the article content on each organization's website. This email is an unaffiliated unofficial redistribution of this freely provided content from the publishers. </strong></p>
<p> </p>
<p><s><small><a href="#" style="color:#ffffff;"><a href="https://blogtrottr.com/unsubscribe/565/NqK6bq">unsubscribe from this feed</a></a></small></s></p>